NCT03530696
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody, Serine-Threonine Kinase Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with known, active, and unstable CNS metastases or carcinomatous meningitis that require treatment
https://ClinicalTrials.gov/show/NCT03530696